和黄医药（中国）有限公司于2026年3月2日披露2月股份变动月报表，报告期截至2026年2月28日。根据公告显示，公司本月股本情况保持稳定，具体如下：
公司注册股本方面，截至2月底法定/注册股本维持在1,500,000,000股，面值每股0.1美元，总额1.5亿美元，与上月底持平。此外，公司已发行股本亦未发生变化，普通股数目仍为872,327,620股，暂无库藏股或注销记录。
根据披露，公司于2015年4月24日有条件采纳的认股权计划下本月无新增授出、行使或失效的股份期权。截至2月底，股份期权余额为25,646,933份，均处于未行使状态，未产生任何因行使期权而新增的股份发行或所得资金。
公告同时确认公司符合香港联交所对于公众持股量的相关要求。截至报告期末，公司总股本及公众持股比例保持不变。公告由非执行董事兼公司秘书施熙德签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.